Progress in diagnosis and treatment of mucinous ovarian cancer

Tong LI; Huijuan YANG

doi:10.19401/j.cnki.1007-3639.2024.01.006

您当前的位置：

首页 >

文章列表页 >

Progress in diagnosis and treatment of mucinous ovarian cancer

Review | 更新时间：2025-12-31

- Progress in diagnosis and treatment of mucinous ovarian cancer
- China Oncology Vol. 34, Issue 1, Pages: 90-96(2024)
- 作者机构：
  
  1. 复旦大学附属肿瘤医院胸外科，复旦大学遗传工程国家重点实验室，复旦大学胸部肿瘤研究所，复旦大学上海医学院肿瘤学系，上海 200032
  2. 复旦大学附属肿瘤医院妇瘤科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
  
  YANG Huijuan.
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.01.006
  CLC： R737.31
- Received：07 August 2023，
  
  Revised：2023-10-27，
  
  Published：30 January 2024
- 稿件说明：
移动端阅览
Tong LI, Huijuan YANG. Progress in diagnosis and treatment of mucinous ovarian cancer[J]. China Oncology, 2024, 34(1): 90-96.
DOI：

Tong LI, Huijuan YANG. Progress in diagnosis and treatment of mucinous ovarian cancer[J]. China Oncology, 2024, 34(1): 90-96. DOI： 10.19401/j.cnki.1007-3639.2024.01.006.

摘要

卵巢黏液性癌（mucinous ovarian cancer，MOC）是卵巢上皮性癌的一种罕见病理学类型，临床上治疗多参考卵巢浆液性癌（serous ovarian cancer，SOC）的相关指南，但由于MOC的临床病理学特征和分子生物学特征与SOC显著不同，因此诊断和治疗均需仔细鉴别。手术联合辅助化疗为目前治疗MOC的标准方案，但由于其患病率低，临床试验难以开展，循证医学证据缺乏，术中阑尾切除指征、术后辅助化疗方案的选择等均缺乏共识。此外，还需进一步转化靶向治疗和免疫治疗的临床前研究，以利于MOC的精准诊断及个体化治疗。

Abstract

Mucinous ovarian cancer (MOC) is a rare pathological type different from epithelial ovarian cancer

and the clinical treatment should refer to serous ovarian cancer (SOC) guidelines. However

since the clinicopathological features of MOC are significantly different from SOC

careful differentiation is needed in diagnosis and treatment. Surgery combined with adjuvant chemotherapy is the standard treatment for MOC. However

due to the low prevalence rate

it is difficult to carry out clinical trials

hence lacking evidence-based medicine and consensus on the indications of intraoperative appendectomy and the choice of postoperative adjuvant chemotherapy. In addition

further translational preclinical studies of targeted therapy and immunotherapy are needed to facilitate the diagnosis and individualized treatment of MOC.

关键词

Keywords

references

MORICE P , GOUY S , LEARY A . Mucinous ovarian carcinoma [J ] . N Engl J Med , 2019 , 380 ( 13 ): 1256 - 1266 . DOI: 10.1056/NEJMra1813254 http://doi.org/10.1056/NEJMra1813254 http://www.nejm.org/doi/10.1056/NEJMra1813254 http://www.nejm.org/doi/10.1056/NEJMra1813254

GATES M A , ROSNER B A , HECHT J L , et al . Risk factors for epithelial ovarian cancer by histologic subtype [J ] . Am J Epidemiol , 2010 , 171 ( 1 ): 45 - 53 . DOI: 10.1093/aje/kwp314 http://doi.org/10.1093/aje/kwp314

KELEMEN L E , KÖBEL M . Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma [J ] . Lancet Oncol , 2011 , 12 ( 11 ): 1071 - 1080 . DOI: 10.1016/S1470-2045(11)70058-4 http://doi.org/10.1016/S1470-2045(11)70058-4

WAGNER B J , BUCK J L , SEIDMAN J D , et al . From the archives of the AFIP. Ovarian epithelial neoplasms: radiologic-pathologic correlation [J ] . Radiographics , 1994 , 14 ( 6 ): 1351 - 1374 ;quiz 1375-1376.

BABAIER A , GHATAGE P . Mucinous cancer of the ovary: overview and current status [J ] . Diagnostics (Basel) , 2020 , 10 ( 1 ): 52 .

ANGLESIO M S , KOMMOSS S , TOLCHER M C , et al . Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas [J ] . J Pathol , 2013 , 229 ( 1 ): 111 - 120 . DOI: 10.1002/path.2013.229.issue-1 http://doi.org/10.1002/path.2013.229.issue-1 https://pathsocjournals.onlinelibrary.wiley.com/toc/10969896/229/1 https://pathsocjournals.onlinelibrary.wiley.com/toc/10969896/229/1

JORDAN S J , GREEN A C , WHITEMAN D C , et al . Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? [J ] . Gynecol Oncol , 2007 , 107 ( 2 ): 223 - 230 .

HESS V , A’HERN R , NASIRI N , et al . Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment [J ] . J Clin Oncol , 2004 , 22 ( 6 ): 1040 - 1044 . DOI: 10.1200/JCO.2004.08.078 http://doi.org/10.1200/JCO.2004.08.078

SIEGEL R , MILLER K , JEMAL A . Cancer statistics, 2019 [J ] . CA Cancer J Clin , 2019 , 69 ( 1 ): 7 - 34 . DOI: 10.3322/caac.v69.1 http://doi.org/10.3322/caac.v69.1 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/69/1 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/69/1

KAJIYAMA H , SUZUKI S , UTSUMI F , et al . Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma [J ] . Int J Clin Oncol , 2019 , 24 ( 8 ): 950 - 956 . DOI: 10.1007/s10147-019-01438-6 http://doi.org/10.1007/s10147-019-01438-6

PERES L C , CUSHING-HAUGEN K L , KÖBEL M , et al . Invasive epithelial ovarian cancer survival by histotype and disease stage [J ] . J Natl Cancer Inst , 2019 , 111 ( 1 ): 60 - 68 . DOI: 10.1093/jnci/djy071 http://doi.org/10.1093/jnci/djy071

PERREN T J . Mucinous epithelial ovarian carcinoma [J ] . Ann Oncol , 2016 , 27 ( Suppl 1 ): i53 - i57 . DOI: 10.1093/annonc/mdw087 http://doi.org/10.1093/annonc/mdw087 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316163 https://linkinghub.elsevier.com/retrieve/pii/S0923753419316163

ATRI M , ALABOUSI A , REINHOLD C , et al . ACR appropriateness criteria ® clinically suspected adnexal mass, No acute symptoms [J ] . J Am Coll Radiol , 2019 , 16 ( 5S ): S77 - S93 . DOI: 10.1016/j.jacr.2019.02.011 http://doi.org/10.1016/j.jacr.2019.02.011 https://linkinghub.elsevier.com/retrieve/pii/S1546144019301516 https://linkinghub.elsevier.com/retrieve/pii/S1546144019301516

MACKENZIE R , KOMMOSS S , WINTERHOFF B J , et al . Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms [J ] . BMC Cancer , 2015 , 15 : 415 . DOI: 10.1186/s12885-015-1421-8 http://doi.org/10.1186/s12885-015-1421-8

CHANG K L , LEE M Y , CHAO W R , et al . The status of HER 2 amplification and KRAS mutations in mucinous ovarian carcinoma [J ] . Hum Genomics , 2016 , 10 ( 1 ): 40 . DOI: 10.1186/s40246-016-0096-9 http://doi.org/10.1186/s40246-016-0096-9 http://humgenomics.biomedcentral.com/articles/10.1186/s40246-016-0096-9 http://humgenomics.biomedcentral.com/articles/10.1186/s40246-016-0096-9

HERRINGTON C S . WHO classification of tumours female genital tumours [M/OL ] . International Agency for Research on Cancer , 2020 .[2023-10-23 ] . https://www.research.ed.ac.uk/en/publications/who-classification-of-tumours-female-genital-tumours https://www.research.ed.ac.uk/en/publications/who-classification-of-tumours-female-genital-tumours https://www.research.ed.ac.uk/en/publications/who-classification-of-tumours-female-genital-tumours.

PRAT J , D'ANGELO E , ESPINOSA I . Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics [J ] . Hum Pathol , 2018 , 80 : 11 - 27 . DOI: S0046-8177(18)30230-2 http://doi.org/S0046-8177(18)30230-2

HUNTER S M , GORRINGE K L , CHRISTIE M , et al . Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations [J ] . Clin Cancer Res , 2012 , 18 ( 19 ): 5267 - 5277 . DOI: 10.1158/1078-0432.CCR-12-1103 http://doi.org/10.1158/1078-0432.CCR-12-1103

SEIDMAN J D , KURMAN R J , RONNETT B M . Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis [J ] . Am J Surg Pathol , 2003 , 27 ( 7 ): 985 - 993 . DOI: 10.1097/00000478-200307000-00014 http://doi.org/10.1097/00000478-200307000-00014

DUNDR P , BÁRTŮ M , BOSSE T , et al . Primary mucinous tumors of the ovary: an interobserver reproducibility and detailed molecular study reveals significant overlap between diagnostic categories [J ] . Mod Pathol , 2023 , 36 ( 1 ): 100040 . DOI: 10.1016/j.modpat.2022.100040 http://doi.org/10.1016/j.modpat.2022.100040 https://linkinghub.elsevier.com/retrieve/pii/S0893395222000400 https://linkinghub.elsevier.com/retrieve/pii/S0893395222000400

NOLEN B , MARRANGONI A , VELIKOKHATNAYA L , et al . A serum based analysis of ovarian epithelial tumorigenesis [J ] . Gynecol Oncol , 2009 , 112 ( 1 ): 47 - 54 . DOI: 10.1016/j.ygyno.2008.09.043 http://doi.org/10.1016/j.ygyno.2008.09.043

AMIN M B , EDGE S B , GREENE F L , et al . AJCC cancer staging manual. 8th ed [M ] . New York : Springer , 2017 : 739 - 747 .

VAN BAAL J , VAN DE VIJVER K K , COFFELT S B , et al . Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study [J ] . BJOG , 2017 , 124 ( 3 ): 486 - 494 . DOI: 10.1111/bjo.2017.124.issue-3 http://doi.org/10.1111/bjo.2017.124.issue-3 https://obgyn.onlinelibrary.wiley.com/toc/14710528/124/3 https://obgyn.onlinelibrary.wiley.com/toc/14710528/124/3

MATSUO K , MACHIDA H , MARIANI A , et al . Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer [J ] . J Gynecol Oncol , 2018 , 29 ( 5 ): e69 . DOI: 10.3802/jgo.2018.29.e69 http://doi.org/10.3802/jgo.2018.29.e69 https://ejgo.org/DOIx.php?id=10.3802/jgo.2018.29.e69 https://ejgo.org/DOIx.php?id=10.3802/jgo.2018.29.e69

HOOGENDAM J P , VLEK C A , WITTEVEEN P O , et al . Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta-analysis [J ] . BJOG , 2017 , 124 ( 3 ): 370 - 378 . DOI: 10.1111/bjo.2017.124.issue-3 http://doi.org/10.1111/bjo.2017.124.issue-3 https://obgyn.onlinelibrary.wiley.com/toc/14710528/124/3 https://obgyn.onlinelibrary.wiley.com/toc/14710528/124/3

GOUY S , SAIDANI M , MAULARD A , et al . Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types [J ] . Gynecol Oncol Rep , 2017 , 22 : 21 - 25 .

ARMSTRONG D K , ALVAREZ R D , BAKKUM-GAMEZ J N , et al . Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2021 , 19 ( 2 ): 191 - 226 . DOI: 10.6004/jnccn.2021.0007 http://doi.org/10.6004/jnccn.2021.0007 https://jnccn.org/view/journals/jnccn/19/2/article-p191.xml https://jnccn.org/view/journals/jnccn/19/2/article-p191.xml

CONLEY A B , FOURNIER K F , SOOD A K , et al . Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for advanced or recurrent mucinous ovarian cancer [J ] . Obstet Gynecol , 2023 , 141 ( 5 ): 1019 - 1023 . DOI: 10.1097/AOG.0000000000005154 http://doi.org/10.1097/AOG.0000000000005154

FIRAT CUYLAN Z , KARABUK E , OZ M , et al . Comparison of stage Ⅲ mucinous and serous ovarian cancer: a case-control study [J ] . J Ovarian Res , 2018 , 11 ( 1 ): 91 . DOI: 10.1186/s13048-018-0464-2 http://doi.org/10.1186/s13048-018-0464-2

MELAMED A , MANNING-GEIST B , BREGAR A J , et al . Associations between residual disease and survival in epithelial ovarian cancer by histologic type [J ] . Gynecol Oncol , 2017 , 147 ( 2 ): 250 - 256 . DOI: S0090-8258(17)31225-8 http://doi.org/S0090-8258(17)31225-8

YOSHIHARA M , KAJIYAMA H , TAMAUCHI S , et al . Impact of uterus-preserving surgery on stage Ⅰ primary mucinous epithelial ovarian carcinoma: a multi-institutional study with propensity score-weighted analysis [J ] . Int J Gynaecol Obstet , 2020 , 150 ( 2 ): 177 - 183 . DOI: 10.1002/ijgo.v150.2 http://doi.org/10.1002/ijgo.v150.2 https://obgyn.onlinelibrary.wiley.com/toc/18793479/150/2 https://obgyn.onlinelibrary.wiley.com/toc/18793479/150/2

BENTIVEGNA E , FRUSCIO R , ROUSSIN S , et al . Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients [J ] . Fertil Steril , 2015 , 104 ( 5 ): 1319 - 1324 . DOI: 10.1016/j.fertnstert.2015.06.008 http://doi.org/10.1016/j.fertnstert.2015.06.008

LEE J Y , JO Y R , KIM T H , et al . Safety of fertility-sparing surgery in primary mucinous carcinoma of the ovary [J ] . Cancer Res Treat , 2015 , 47 ( 2 ): 290 - 297 . DOI: 10.4143/crt.2014.004 http://doi.org/10.4143/crt.2014.004 http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.004 http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.004

KAJIYAMA H , SHIBATA K , MIZUNO M , et al . Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary [J ] . Gynecol Oncol , 2011 , 122 ( 2 ): 334 - 338 . DOI: 10.1016/j.ygyno.2011.04.016 http://doi.org/10.1016/j.ygyno.2011.04.016

ROSENDAHL M , HAUEBERG OESTER L A , HØGDALL C K . The importance of appendectomy in surgery for mucinous adenocarcinoma of the ovary [J ] . Int J Gynecol Cancer , 2017 , 27 ( 3 ): 430 - 436 . DOI: 10.1097/IGC.0000000000000910 http://doi.org/10.1097/IGC.0000000000000910

LIN J E , SEO S , KUSHNER D M , et al . The role of appendectomy for mucinous ovarian neoplasms [J ] . Am J Obstet Gynecol , 2013 , 208 ( 1 ): 46. e1 - 46 .e4.

BAMIAS A , SOTIROPOULOU M , ZAGOURI F , et al . Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor [J ] . Eur J Cancer , 2012 , 48 ( 10 ): 1476 - 1483 . DOI: 10.1016/j.ejca.2011.09.023 http://doi.org/10.1016/j.ejca.2011.09.023

TRIMBOS J B , PARMAR M , VERGOTE I , et al . International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase Ⅲ trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma [J ] . J Natl Cancer Inst , 2003 , 95 ( 2 ): 105 - 112 . DOI: 10.1093/jnci/95.2.105 http://doi.org/10.1093/jnci/95.2.105 https://academic.oup.com/jnci/article/95/2/105/2964945 https://academic.oup.com/jnci/article/95/2/105/2964945

LEDERMANN J A , LUVERO D , SHAFER A , et al . Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma [J ] . Int J Gynecol Cancer , 2014 , 24 ( 9 Suppl 3 ): S14 - S19 . DOI: 10.1097/IGC.0000000000000296 http://doi.org/10.1097/IGC.0000000000000296 https://ijgc.bmj.com/lookup/doi/10.1097/IGC.0000000000000296 https://ijgc.bmj.com/lookup/doi/10.1097/IGC.0000000000000296

NASIOUDIS D , HAGGERTY A F , GIUNTOLI R L Ⅱ , et al . Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma [J ] . Gynecol Oncol , 2019 , 154 ( 2 ): 302 - 307 . DOI: S0090-8258(19)31233-8 http://doi.org/S0090-8258(19)31233-8

KURNIT K C , SINNO A K , FELLMAN B M , et al . Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma [J ] . Obstet Gynecol , 2019 , 134 ( 6 ): 1253 - 1259 . DOI: 10.1097/AOG.0000000000003579 http://doi.org/10.1097/AOG.0000000000003579

VAN DRIEL W J , KOOLE S N , SIKORSKA K , et al . Hyperthermic intraperitoneal chemotherapy in ovarian cancer [J ] . N Engl J Med , 2018 , 378 ( 3 ): 230 - 240 . DOI: 10.1056/NEJMoa1708618 http://doi.org/10.1056/NEJMoa1708618 http://www.nejm.org/doi/10.1056/NEJMoa1708618 http://www.nejm.org/doi/10.1056/NEJMoa1708618

MERCIER F , BAKRIN N , BARTLETT D L , et al . Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE [J ] . Ann Surg Oncol , 2018 , 25 ( 6 ): 1668 - 1675 . DOI: 10.1245/s10434-018-6464-z http://doi.org/10.1245/s10434-018-6464-z

张德普 , 孙阳 , 张师前 , 等 . 黏液性卵巢癌诊断与治疗中国专家共识(2021年版) [J ] . 中国微创外科杂志 , 2021 , 21 ( 7 ): 577 - 588 .

ZHANG D P , SUN Y , ZHANG S Q , et al . Chinese expert consensus on the diagnosis and treatment of mucinous ovarian cancer (2021 edition) [J ] . Chin J Minim Inva Surg , 2021 , 21 ( 7 ): 577 - 588 .

GORRINGE K L , CHEASLEY D , WAKEFIELD M J , et al . Therapeutic options for mucinous ovarian carcinoma [J ] . Gynecol Oncol , 2020 , 156 ( 3 ): 552 - 560 . DOI: S0090-8258(19)31836-0 http://doi.org/S0090-8258(19)31836-0

RICCI F , GUFFANTI F , AFFATATO R , et al . Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer [J ] . Am J Cancer Res , 2020 , 10 ( 2 ): 572 - 580 .

WU Y S , SHUI L , SHEN D , et al . Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials [J ] . Oncotarget , 2017 , 8 ( 6 ): 10703 - 10713 . DOI: 10.18632/oncotarget.12926 http://doi.org/10.18632/oncotarget.12926

MCALPINE J N , WIEGAND K C , VANG R , et al . HER 2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy [J ] . BMC Cancer , 2009 , 9 : 433 . DOI: 10.1186/1471-2407-9-433 http://doi.org/10.1186/1471-2407-9-433

VAN CUTSEM E , KÖHNE C H , HITRE E , et al . Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer [J ] . N Engl J Med , 2009 , 360 ( 14 ): 1408 - 1417 . DOI: 10.1056/NEJMoa0805019 http://doi.org/10.1056/NEJMoa0805019 http://www.nejm.org/doi/abs/10.1056/NEJMoa0805019 http://www.nejm.org/doi/abs/10.1056/NEJMoa0805019

SATO N , SAGA Y , MIZUKAMI H , et al . Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations [J ] . Oncol Rep , 2012 , 27 ( 5 ): 1336 - 1340 .

INABA K , ODA K , AOKI K , et al . Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging [J ] . Oncotarget , 2016 , 7 ( 20 ): 29577 - 29591 . DOI: 10.18632/oncotarget.8807 http://doi.org/10.18632/oncotarget.8807

SEGEV Y , PAL T , ROSEN B , et al . Risk factors for ovarian cancers with and without microsatellite instability [J ] . Int J Gynecol Cancer , 2014 , 24 ( 4 ): 664 - 669 . DOI: 10.1097/IGC.0000000000000134 http://doi.org/10.1097/IGC.0000000000000134

PAL T , PERMUTH-WEY J , KUMAR A , et al . Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology [J ] . Clin Cancer Res , 2008 , 14 ( 21 ): 6847 - 6854 . DOI: 10.1158/1078-0432.CCR-08-1387 http://doi.org/10.1158/1078-0432.CCR-08-1387

MURPHY M A , WENTZENSEN N . Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America [J ] . Int J Cancer , 2011 , 129 ( 8 ): 1914 - 1922 . DOI: 10.1002/ijc.25835 http://doi.org/10.1002/ijc.25835

DIAZ L A , MARABELLE A , DELORD J P , et al . Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC [J ] . J Clin Oncol , 2017 , 35 ( 15_suppl ): 3071 . DOI: 10.1200/JCO.2017.35.15_suppl.3071 http://doi.org/10.1200/JCO.2017.35.15_suppl.3071 http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.3071 http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.3071

MEAGHER N S , HAMILTON P , MILNE K , et al . Profiling the immune landscape in mucinous ovarian carcinoma [J ] . Gynecol Oncol , 2023 , 168 : 23 - 31 . DOI: 10.1016/j.ygyno.2022.10.022 http://doi.org/10.1016/j.ygyno.2022.10.022 https://linkinghub.elsevier.com/retrieve/pii/S0090825822018996 https://linkinghub.elsevier.com/retrieve/pii/S0090825822018996

Views

4557

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress in diagnosis and treatment of gynecological tumors in 2022

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer

Progress in treatment of gynecological cancer in 2023

The latest progress and prospect of gynecological tumor treatment at 2023 ESMO

Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer

Related Author

Qinhao GUO

Min YU

Xiaohua WU

Yanan TIAN

Hui ZHENG

Tianqing YAN

Heng ZHANG

Renquan LU

Related Institution

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University

Department of Oncology, Shanghai Medical College, Fudan University

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center

AI问答

⁰